Company Performance - Waters reported quarterly earnings of $2.95 per share, exceeding the Zacks Consensus Estimate of $2.93 per share, and up from $2.63 per share a year ago, representing an earnings surprise of +0.68% [1] - The company posted revenues of $771.33 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 3.63%, compared to $708.53 million in the same quarter last year [2] - Over the last four quarters, Waters has consistently surpassed consensus EPS and revenue estimates [2] Stock Outlook - Waters shares have declined approximately 21.8% since the beginning of the year, while the S&P 500 has gained 6.1% [3] - The company's current Zacks Rank is 3 (Hold), indicating expected performance in line with the market in the near future [6] - The consensus EPS estimate for the upcoming quarter is $3.24 on revenues of $777.06 million, and for the current fiscal year, it is $12.91 on revenues of $3.11 billion [7] Industry Context - The Medical - Instruments industry, to which Waters belongs, is currently ranked in the bottom 37% of over 250 Zacks industries, suggesting potential challenges ahead [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact investor sentiment [5]

Core Viewpoint - iRadimed (IRMD) reported quarterly earnings of $0.49 per share, exceeding the Zacks Consensus Estimate of $0.45 per share, and showing an increase from $0.42 per share a year ago, indicating a positive earnings surprise of +8.89% [1] Group 1: Earnings Performance - The company achieved revenues of $20.41 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 0.49% and up from $17.93 million year-over-year [2] - Over the last four quarters, iRadimed has exceeded consensus EPS estimates two times and topped consensus revenue estimates four times [2] Group 2: Stock Performance and Outlook - iRadimed shares have increased approximately 6.1% since the beginning of the year, while the S&P 500 has gained 7.8% [3] - The company's earnings outlook will be crucial for future stock performance, with current consensus EPS estimates at $0.44 for the upcoming quarter and $1.76 for the current fiscal year [7] Group 3: Industry Context - The Medical - Instruments industry, to which iRadimed belongs, is currently ranked in the bottom 37% of over 250 Zacks industries, which may impact stock performance [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, suggesting that investors should monitor these revisions closely [5]

Waters (WAT) came out with quarterly earnings of $2.25 per share, beating the Zacks Consensus Estimate of $2.22 per share. This compares to earnings of $2.21 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 1.35%. A quarter ago, it was expected that this maker of products used in drug discovery and development would post earnings of $4.02 per share when it actually produced earnings of $4.10, delivering a surprise of 1.99%.Over ...

Group 1 - Idexx Laboratories reported quarterly earnings of $2.96 per share, exceeding the Zacks Consensus Estimate of $2.92 per share, and showing an increase from $2.81 per share a year ago, representing an earnings surprise of 1.37% [1] - The company posted revenues of $998.43 million for the quarter ended March 2025, which was below the Zacks Consensus Estimate by 1.77%, but an increase from $964.1 million year-over-year [2] - Idexx has surpassed consensus EPS estimates three times over the last four quarters and topped consensus revenue estimates two times during the same period [2] Group 2 - The stock has gained approximately 4.7% since the beginning of the year, contrasting with the S&P 500's decline of -5.3% [3] - The current consensus EPS estimate for the upcoming quarter is $3.26 on revenues of $1.06 billion, and for the current fiscal year, it is $11.96 on revenues of $4.09 billion [7] - The Medical - Instruments industry, to which Idexx belongs, is currently ranked in the top 23% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8]